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Abstract
The main purpose of this in situ hybridiza-
tion study was to investigate mRNA expression
of three bone/cartilage matrix components
(perlecan, DMP1, and MEPE) in developing
primary (tibial) and secondary (condylar) car-
tilage. Perlecan mRNA expression was first
detected in newly formed chondrocytes in tib-
ial cartilage at E13.0, but this expression
decreased in hypertrophic chondrocytes at
E14.0. In contrast, at E15.0, perlecan mRNA
was first detected in the newly formed chon-
drocytes of condylar cartilage; these chondro-
cytes had characteristics of hypertrophic chon-
drocytes, which confirmed the previous obser-
vation that progenitor cells of developing sec-
ondary cartilage rapidly differentiate into
hypertrophic chondrocytes. DMP1 mRNA was
detected in many chondrocytes within the
lower hypertrophic cell zone in tibial cartilage
at E14.0. In contrast, DMP1 mRNA expression
was only transiently detected in a few chondro-
cytes of condylar cartilage at E15.0. Thus,
DMP1 may be less important in the developing
condylar cartilage than in the tibial cartilage.
Another purpose of this study was to test the
hypothesis that MEPE may be a useful marker
molecule for cartilage. MEPE mRNA was not
detected in any chondrocytes in either tibial or
condylar cartilage; however, MEPE immunore-
activity was detected throughout the cartilage
matrix. Western immunoblot analysis demon-
strated that MEPE antibody recognized two
bands, one of 67 kDa and another of 59 kDa, in
cartilage-derived samples. Thus MEPE protein
may gradually accumulate in the cartilage,
even though mRNA expression levels were
below the limits of detection of in situ
hybridization. Ultimately, we could not desig-
nate MEPE as a marker molecule for cartilage,
and would modify our original hypothesis.
Introduction
Mandibular condylar cartilage is embryolog-
ically classified as secondary cartilage.1-3
Secondary cartilage is somewhat different
from primary cartilage; for example, it differs
in origin, time of its appearance, and pattern
of expression for several matrix components
and growth factors.1-6 Previously, we reported
that mouse condylar cartilage derives from
alkaline phosphatase (ALP)-positive progeni-
tor cells of the periosteum that is continuous
with the ossifying mandible that forms before
the condylar cartilage.7 Meanwhile, extracellu-
lar matrix (ECM) components are involved in
organogenesis of bone or cartilage, and often
utilized as marker molecules for each organ.3
From this point of view, we investigated
expression patterns of bone/cartilage matrix
components, including collagen types I, II, X,
aggrecan, bone sialoprotein (BSP), and osteo-
pontin (OPN) (secreted phosphoprotein-
1:Spp-1).7-9 These previous studies confirm
that expression patterns of matrix components
in developing condylar cartilage differ from
those in limb bud cartilage (representative pri-
mary cartilage), and they demonstrate that
progenitor cells of condylar cartilage rapidly
differentiate into hypertrophic chondrocytes.
In the present in situ hybridization study, we
focused on three other bone/cartilage matrix
components, which involved cartilage forma-
tion and mineralization, to further elucidate
structural features of developing condylar car-
tilage and limb bud cartilage.
Perlecan is a large heparan sulfate proteo-
glycan that is present in basement membranes
and other extracellular matrices.10-13 It has a
wide variety of functions in normal develop-
ment and disease processes; these roles
include binding to other extracellular proteins,
growth factors, and cell membrane receptors.14
Additionally, perlecan-deficient mice display
severe chondrodysplasia, which includes disor-
ganized collagen fibrils and poor glycosamino-
glycans, and this phenotype revealed that per-
lecan is essential for normal cartilage forma-
tion.15,16 However, transition of perlecan mRNA
expression in the mesenchymal cell condensa-
tion to the initial formation of cartilage in nor-
mal mice has not been reported for either sec-
ondary cartilage or primary cartilage. Thus,
investigation of perlecan mRNA expression
would clarify further structural features of both
types of cartilage.
DMP1 (dentin matrix protein 1) was first
identified as a product of a rat pulp incisor
cDNA library; it belongs to SIBLING (small
integrin-binding ligand, N-linked glycopro-
tein) protein family, and previously it was
thought to be dentin-specific.17 Subsequently,
high levels of DMP1 mRNA were detected in
osteocytes and lower levels were seen in other
mineralized or unmineralized tissues such as
dental pulp, brain, and submandibular
glands.18-22 Regarding cartilage, DMP1mRNA is
expressed in hypertrophic chondrocytes in
fetal limb bud cartilage at E16.0, and this
expression in hypertrophic chondrocytes per-
sisted throughout later embryonic and post-
natal development, indicating involvement of
this molecule in cartilage mineralization.23
Based on immunohistochemistry, DMP1 pro-
tein localization is complicated; for example,
full-length DMP1 (108 kDa) and two proteolytic
fragments (a 37-kDa N-terminal fragment and
a 57-kDa C-terminal fragment) have different
localization patterns in two different types of
cartilage: limb bud cartilage24 and postnatal rat
mandibular condylar cartilage.25 Thus, investi-
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gation of DMP1 mRNA expression during the
initial stages of cartilage formation would clar-
ify features of both types of cartilage in terms
of mineralization. 
MEPE (matrix extracellular phosphoglyco-
protein), like DMP1, is a member of the SIB-
LING family and a bone marker protein
expressed in osteocytes.26,27 MEPE is also
expressed in odontoblasts, regenerating tis-
sues after a fracture, and tumor tissue.28,29
Stain et al.30 recently reported that MEPE
mRNA is expressed in hypertrophic chondro-
cytes in the growth plate of 3-week-old mice.
However, expression of MEPE mRNA during
the initial stages of cartilage formation was
not investigated in any type of cartilage. Thus,
the main purpose of this in situ hybridization
study was to examine the expression of per-
lecan, DMP1, and MEPE mRNA in the develop-
ing mandibular condylar cartilage and the
developing limb bud cartilage. In addition, we
previously reported that MEPE immunoreactiv-
ity was clearly evident throughout the matrix
of Meckel’s cartilage in mice, rats, and
humans; 31 consequently, we hypothesized that
MEPE may be a useful marker molecule for car-
tilage. Thus another purpose of this study is to




A total of 10 pregnant ICR mice, stage E12.0-
18.0 (8 a.m. on the day of the vaginal plug was
designated as stage E0), and five male 3-
weeks-old mice were used for this study. Each
animal was housed in facilities approved by
Tokyo Medical and Dental University. Our ani-
mal-use protocol and experimental system
were approved by the Institutional Animal Care
and Use Committee of Tokyo Medical and
Dental University (No. 0150011A).RT-PCR
Mandibular condylar anlage or formed condy-
lar cartilage was meticulously microdissected
from embryonic mice at specific points within
the E14.0-E16.0 window. ISOGEN (Nippon
Gene, Tokyo, Japan) was used to extract total
RNA from condylar cartilage of E15.0 and E16.0
and condylar anlage from E14.0. Primer Script
RT reagent Kit and gDNA Eraser (Takara Bio
Inc., Shiga, Japan) were used for RT-PCR to
synthesize cDNA. SybrGreen Premix EX Taq II
(Takara Bio Inc, Shiga, Japan) and a Light
Cycler 480 Real-Time PCR System (Roche
Diagnostics, Tokyo, Japan) were used for all
real-time PCR amplification. Each primer
sequence is listed in Table 1. The PCR condi-
tions were as follows: initial denaturing at 95°C
for 30 s followed by 40 cycles of denaturing at
95°C for 5 s, annealing at 60°C for 30 s, exten-
sion at 72°C for 30 s, and a final extension at
72°C for 7.5 min. b-actin mRNA levels were
quantified as internal controls. Relative expres-
sion levels were calculated using the Δ(ΔCt)
method. All data are expressed as the mean ±
SD. The data analyses were performed with
one-way analysis of variance for several group
comparisons, and significance was determined
using Tukey’s comparison test. A P-value of
<0.01 was considered statistically significant.
We examined three different samples for each
embryonic day.Tissue preparation
At each time point, pregnant mice were
killed by cervical dislocation under ether anes-
thesia, after which each fetal mouse was killed
by cervical dislocation. The heads and lower
limbs were removed and then immersed in 4%
paraformaldehyde (0.1 M phosphate buffer, pH
7.4) for 1 day at 4°C. Paraffin embedded serial
sections (5 mm) were cut in the coronal plane
(perpendicular to the sagittal plane) and paral-
lel to the long axis of the condylar process of
the mandible or longitudinally to the tibia.
Sections were stained with 0.1% toluidine blue
(0.1 M phosphate buffer, pH 7.4) for histologi-
cal observations.In situ hybridization
For in situ hybridization of perlecan, DMP1,
and MEPE, total RNA was extracted from limb
cartilage and bone; cDNA encoding mouse per-
lecan (NM_008305.3), DMP1 (NM_016779.2),
and MEPE (NM_053172.2), were then synthe-
sized via RT-PCR. Each primer sequence is
listed in Table 2. A representative PCR product
for each gene was subcloned into a pCRII vec-
tor (Strategene, La Jolla, CA, USA); antisense
and sense RNA probes were then synthesized
for each gene. The Riboprobe in vitro
Transcription System (Promega, Madison, WI)
was used to label each probe with 35S-UTP. In
situ hybridization with 35S-UTP labeled probes
was performed as previously described.32-34
Sections were dipped in emulsion (NTB,
Kodak, Rochester, NY, USA) after hybridization
and RNAase treatment, and then exposed for 2
weeks at 4°C for autoradiography. We extend-
ed exposure period up to 4 weeks to confirm
enhanced signals would appear, but they were
not recognized. Sense probes were used for
negative control samples.  We examined three
different samples for each embryonic day, and
the same results were obtained each time.
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Table 1. Primer sets for real-time PCR. 
cDNA                       Primer sequence (5'→3')                                                   Size
Perlecan                          Forward: AGCCGCAGCAAGGACTTCA                                                     174 bp
                                         Reverse: CGTCTACTTGGATGGAGCCTCT                                                    
DMP1                               Forward: AGCTGGGCTACATTGCTTTGG                                                155 bp
                                         Reverse: TCCAGGCTTTGCTACTGTGGAAC                                                 
MEPE                                Forward: GAGTCGTCATCCAGTGGGAGTTC                                          171 bp
                                         Reverse: AGGTCTGTTGGCTTGCTCAGTTC                                                 
Aggrecan                         Forward: AGTGGATCGGTCTGAATGACAGG                                          105 bp
                                         Reverse: AGAAGTTGTCAGGCTGGTTTGGA                                                 
b-actin                            Forward: CATCCGTAAAGACCTCTATGCCAAC                                        171 bp
                                         Reverse: ATGGAGCCACCGATCCACA                                                            
DMP1, dentin matrix protein 1; MEPE, matrix extracellular phosphoglycoprotein.
Table 2. Primer sets for RNA probes.
cDNA                       Primer sequence (5'→3')                                                 Size
Perlecan                           Forward: CCGGGCTCTGGTAAATTTTA                                                  791 bp
                                          Reverse: CTGCCATCCCTGCAGTCTTC                                                       
DMP1                                Forward: GTGCTCTCCCAGTTGCCAGATA                                            373 bp
                                          Reverse: TGATGAGGACTCCACAGACAC                                                     
MEPE                                Forward: CTCCAGCAAAGCTGAAGT                                                      611 bp
                                          Reverse: GACAGCAGCGAGTCGTCATC                                                      
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Immunohistochemistry
A rat monoclonal antibody against perlecan
(diluted 1:200 with PBS) was purchased from
Seikagaku Corp (Tokyo, Japan). Rabbit poly-
clonal antibody against MEPE, LF-155 (diluted
1:200), was kindly supplied by Dr. Larry W.
Fisher (Matrix Biology Unit, Craniofacial and
Skeletal Disease Branch, NIDCR, NIH,
Bethesda, MD, USA). LF-155 reacts only
against COOH-terminal fragments of
MEPE.35,36 For detection of DMP1, mouse mon-
oclonal antibody raised against rat DMP1 57-
kDa fragments was used (diluted 1:500). This
monoclonal antibody specifically recognizes C-
terminal fragments of DMP1.37 These antibod-
ies were well characterized and used in our
previous immunohistochemical studies.31,37,38
Before antibody addition, the sections were
immersed in PBS and digested with testicular
hyaluronidase (25 mg/mL in phosphate
buffered saline; Sigma Chemical Co., St. Louis,
MO, USA) to remove masking with hyaluronan
and chondroitin sulphate chains for 3 h at
37°C. Sections for DMP1 immunohistochem-
istry were then immersed in mouse IgG block-
ing reagent from a MOM kit (Vector
Laboratories, Burlingame, CA, USA) to block
endogenous mouse IgG activity. The strepta-
vidin-biotin method with a Histofine SAB kit
(Nichirei, Tokyo, Japan) was then performed
as previously described.7,31,38,39 The sections
were treated with diaminobenzidine to visual-
ize protein localization. Negative control sec-
tions were incubated with normal rabbit or
mouse or rat IgG instead of the primary anti-
bodies. Sections were observed after counter-
staining with hematoxylin. Protein extraction from bone andcartilage 
Under anesthesia with diethyl ether and
intraperitoneal injection of pentobarbital sodi-
um (30 mg/kg body weight) (Kyoritu, Tokyo,
Japan), bone of limbs, ribs, vertebra, and cal-
varia were dissected from 3-weeks-old mice
and homogenized. The samples (2.8 g wet wt)
were stirred for 72 h at 4°C in 30 mL of an E-
extraction buffer (4 M guanidine HCl, 50 mM
sodium acetate, 0.5 M Tetrasodium EDTA, pH
7.4) that contained a protease-inhibitor cock-
tail (Sigma-Aldrich).40 After centrifugation, the
supernatant was removed and the remaining
residues were stirred in the same buffer for
another 72 h. The solution was again cen-
trifuged, the supernatant removed and mixed
with the first extract. The solution was dia-
lyzed with 0.5 M Sodium Acetate (pH 7.4) con-
taining protease inhibitors for 24 h at 4°C.
Precipitated insoluble proteins (presumably
collagen) were removed by centrifugation, and
the supernatant was again dialyzed with dH2O
for another 48 h and freeze-dried (bone-
derived samples). Meanwhile, to collect large
amounts of pure cartilage without bone, tra-
cheal cartilage (6 mg wet wt) was dissected
and stirred in 6 mL  of an G-extraction buffer
(4 M guanidine HCl, 50 mM sodium acetate,
pH 7.4) containing protease inhibitors cock-
tail.40 The following steps were performed as
described for bone-derived samples.  Other tra-
cheal cartilage specimens were fixed and
embedded in paraffin, then subjected to
immunohistochemistry to confirm whether
postnatal tracheal cartilage also shows MEPE
immunoreactivity.Electrophoresis and Westernimmunoblotting
Samples of bone- or cartilage-derived pro-
tein (~100 ng) were subjected to SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE)
in12.5% (W/V) gel. SDS-PAGE was done under
reducing conditions, and protein bands were
transferred to Immobilon-P membranes with
Horizblot from ATTO (Tokyo, Japan). The
membranes were then immersed in a solution
of 3% bovine serum albumin in PBS for 1 h at
RT to block any non-specific reactions. They
were then reacted with mouse monoclonal
antibody that was against a 57-kDa fragment
of rat DMP1 (diluted 1:2000 with PBS) or rab-
bit polyclonal antibody against MEPE, LF-155
(diluted 1:1000), in PBS at 4°C overnight. The
membranes were then incubated in biotin-
labeled anti-mouse IgG+IgA+IgM (diluted 1:10
with PBS) or biotin-labeled anti-rabbit IgG
(diluted 1:10) from HISTOFINE SAB kits for 1
h at 37°C, and subsequently incubated in per-
oxidase-labelled streptoavidin (diluted 1:10
with PBS) for 30 min at RT. Membranes were
then washed in PBS and next treated with AEC
(Nichirei) to detect any immunoreactivity. The
membranes generated to detect MEPE were
treated with ECL detection system (GE
Healthcare UK Ltd., Little Chalfont, UK) and
exposed to soft X-ray film.
ResultsRT-PCR analysis of perlecan,DMP1, and MEPE mRNA in devel-oping mandibular condylar cartilage
Based on RT-PCR analysis, aggrecan mRNA
was barely evident in the condylar anlagen at
E14.0. Aggrecan mRNA expression levels had
increased modestly by E15.0 and were marked-
ly upregulated by E16.0 (Figure 1a). Perlecan
mRNA expression on E14.0 was similar to that
on E15.0, but levels increased 2-fold by E16.0
(Figure 1b). In contrast, neither DMP1 nor
MEPE mRNAs was evident from E14.0 to E16.0
(Figure 1 c,d).
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Figure 1. Real-time PCR analysis of perlecan, DMP1, and MEPE mRNA in condylar cartilage. a) Aggrecan mRNA was barely evident
in the condylar anlagen at E14.0; aggrecan mRNA expression levels had increased modestly by E15.0 and were markedly upregulated
by E 16.0. b) Perlecan mRNA expression on E14.0 was similar to that on E15.0, but levels increased 2-fold by E16.0. c, d) Neither
DMP1 nor MEPE mRNAs was evident from E14.0 to E16.0. Data are presented as means ± SD (n=3).
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In situ hybridization in developingmandibular condylar cartilage
Mandibular bone that contained many
osteocytes was evident on E18.0 (Figure 2a).
DMP1 mRNA was expressed in many of these
osteocytes (Figure 2b); in contrast, MEPE
mRNA was expressed in fewer of these
mandibular bone osteocytes (Figure 2c).
These expression patterns were similar to pat-
terns seen in previous studies,18,26 indicating
probes for DMP1 and MEPE could be reliably
used for this in situ hybridization study. At
E14.0, the anlage of the future mandibular
condylar process (designated the condylar
anlage) was recognizable in the posterior posi-
tion of the ossifying mandible, which com-
prised osteoid-like tissue. The condylar anlage
consisted of a mesenchymal cell condensation,
as previously described.6-9,33 Cartilage forma-
tion indicated by matrix metachromasia was
not observed in the anlage (Figure 3a).
Perlecan mRNA was not detected in the anlage
at this stage (Figure 3b). DMP1 mRNA was
slightly expressed in cells in the osteoid-like
tissue, but not in the condylar anlage (Figure
3c). MEPE mRNA expression was not detected
in the condylar anlage or in the osteoid-like
tissue (Figure 3d). At E15.0, a metachromati-
cally stained matrix, which indicated that the
condylar cartilage had formed, was first detect-
ed in posterior to the ossifying mandible
(Figure 3e). Several chondrocytes in this
newly formed cartilage showed marked hyper-
trophy. The bone collar had formed around the
cartilage (Figure 3e). Perlecan mRNA expres-
sion was detected in newly formed chondro-
cytes (Figure 3f). DMP1 mRNA was expressed
in the osteogenic cells of the bone collar and of
the mandibular bone as well as in a few chon-
drocytes (Figure 3g). MEPE mRNA expression
was barely detected both in the cartilage and
the mandibular bone (Figure 3h). At E16.0, the
condylar cartilage had increased in length,
especially the hypertrophic cell zone; each
zone had become clearly identifiable and dis-
tinct. In this study, condylar cartilages were
classified according to the system developed by
Luder et al.:41 fibrous cell (articular cell) zone,
polymorphic cell zone, flattened cell zone, and
hypertrophic cell zone (Figure 3i). Perlecan
mRNA was expressed in chondrocytes from
flattened cell zone to upper hypertrophic cell
zone, but perlecan mRNA expression was
reduced in the lower hypertrophic cell zone
(Figure 3j). At E16.0, DMP1 mRNA was
expressed in osteogenic cells of the bone col-
lar, but not in chondrocytes (Figure 3k). MEPE
mRNA expression was detected in a few osteo-
cytes in mandibular bone, as described in
Figure 2b (data not shown), but not in the
bone collar or in the cartilage (Figure 3l). 
In situ hybridization in developing tibia
At E12.0, the anlage of the future tibia con-
sisted of a mesenchymal cell condensation
(Figure 4a). At this stage, in situ hybridization
for perlecan, DMP1, and MEPE failed to show
any positive reaction in this condensation
(Figure 4 b-d). At E13.0, the anlage of the
future tibia exhibited metachromasia by tolui-
dine blue staining, indicating initial cartilage
formation; this cartilage was designated tibial
cartilage (Figure 4e); Perlecan mRNA was
expressed in chondrocytes throughout this car-
tilage (Figure 4f), but DMP1 and MEPE mRNA
was not detected in tibial cartilage at this stage
(Figure 4 g,h). At E14.0, chondrocyte hypertro-
phy was first observed in the diaphysis of the
tibial cartilage. At this stage, the hypertrophic
cell zone could be divided into two zones: the
upper hypertrophic cell zone, which contained
relatively large hypertrophic cells, and the
lower hypertrophic cell zone, which was locat-
ed in the center of diaphysis and contained rel-
atively small hypertrophic chondrocytes
(Figure 4i). Perlecan mRNA was strongly
expressed in chondrocytes throughout the
entire proliferation and maturation zone, but
expression was weaker in the hypertrophic cell
zone (Figure 4j). DMP1 mRNA was expressed
in osteogenic cells of the bone collar and in
many hypertrophic chondrocytes of the lower
hypertrophic cell zone (Figure 4k). MEPE
mRNA expression was not detected at this
stage (Figure 4l). Negative controls using
sense probes showed no positive reactions at
any stage examined (data not shown).
Expression patterns of mRNA for three mole-
cules were summarized in Figure 5. Immunohistochemistry in develop-ing mandibular condylar cartilageand tibial cartilage 
In developing condylar cartilage at E14.0,
perlecan immunoreactivity was evident in
Meckel’s cartilage, but not in the anlage
(Figure 6a). DMP1 immunoreactivity was
weak but definite in the osteoid-like tissue,
but it was not evident in the condylar anlage or
Meckel’s cartilage (Figure 6b). MEPE
immunoreactivity was not detected in the
condylar anlage, but it was evident in the
osteoid-like tissue and in Meckel’s cartilage
(Figure 6c). At E15.0, perlecan immunoreactiv-
ity was clearly detected in newly formed carti-
lage matrix (Figure 6d); DMP1 immunoreac-
tivity was evident in the bone collar, but not in
the cartilage matrix (Figure 6e); MEPE
immunoreactivity was evident in the bone col-
lar and in the cartilage matrix (Figure 6f). At
E16.0, perlecan immunoreactivity was detected
throughout the cartilage matrix (Figure 6g);
DMP1 immunoreactivity was detected in the
bone collar, but not in the cartilage matrix
(Figure 6h); MEPE immunoreactivity was
detected in the bone collar and throughout the
cartilage matrix (Figure 6i). In developing
limb bud cartilage at E12.0, immunohisto-
chemistry for perlecan, DMP1, and MEPE
failed to show any positive reaction in the in
the tibial anlage (Figure 6 j-l). At E13.0, per-
lecan and MEPE immunoreactivity was evident
throughout the cartilage matrix (Figure 6
m,o); DMP1 immunoreactivity was not detect-
ed at this stage (Figure 6n). At E14.0, perlecan
immunoreactitivity was detected throughout
the cartilage matrix (Figure 6p); DMP1
immunoreactivity was detected in the bone
collar and in the lower hypertrophic cell zone
(Figure 6q); MEPE immunoreactivity was
detected in the bone collar and throughout the
cartilage matrix (Figure 6r). In maxillary
region at E16.0, MEPE immunoreactivity was
detected in some bone lacunae, but not in the
oral epithelium in the same section (Figure 6
s,t), supporting the specificity of the antibody
used in the present study. 
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Figure 2. A higher magnification of mandibular bone at E18.0. Toluidine blue staining
(a) and in situ hybridization for DMP1 (b) and MEPE (c). Mandibular bone contained
many osteocytes (arrowheads in a). DMP1 mRNA was expressed in many of these osteo-
cytes (arrowhead in b), but MEPE mRNA was expressed in fewer of them (arrowheads in
c). Scale bars: 100 µm.
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Western immunoblotting for DMP1and MEPE in bone- or cartilage-derived samples
Tracheal cartilage from 3-week-old animals
exhibited metachromasia throughout the car-
tilage (Figure 7a). DMP1 immunoreactivity
was not detected in the cartilage matrix
(Figure 7b), but MEPE immunoreactivity was
clearly recognized in the cartilage matrix, as
seen in fetal cartilages (Figure 7c). 
Western immunoblotting indicated that
DMP1 antibody clearly recognized a strong pro-
tein band of 65 kDa in bone-derived samples,
but a weaker band in cartilage-derived samples
(Figure 7d). MEPE antibody recognized a pro-
tein band of 62 kDa in bone-derived samples
and two bands, one of 67 kDa and another of 59
kDa, in cartilage-derived samples (Figure 7e). 
DiscussionPerlecan
In the present study, we first reported tran-
sition of perlecan mRNA expression from mes-
enchymal cell condensation to initial cartilage
formation in normal limb bud cartilage using
in situ hybridization. Perlecan mRNA expres-
sion was not detected in mesenchymal cell
condensations at E12.0; it was first detected in
the newly formed cartilage at E13.0. At E14.0,
perlecan mRNA expression was weak in hyper-
trophic chondrocytes of the diaphysis.
Meanwhile, perlecan immunoreactivity was
evident throughout the tibial cartilage; these
findings indicated that cells developing into
mature chondrocytes actively synthesized per-
lecan, but the hypertrophic chondrocytes had
downregulated perlecan synthesis. This discor-
dance between mRNA expression and protein
accumulation was similar to the discordance
noted for aggrecan localization in the tibial
cartilage.42 
In the condylar cartilage, perlecan mRNA
expression was not detected in the E14.0
anlage, which consisted of mesenchymal cell
condensation: it was first detected in newly
formed cartilage at E15.0. We have previously
described that, as newly formed chondrocytes
can simultaneously express collagen type I, II,
X, and aggrecan, progenitor cells of condylar
cartilage rapidly differentiate into hyper-
trophic chondrocytes; notably, this process is
different from that in limb bud cartilage.6,7,9
Our current results indicated that newly
formed hypertrophic chondrocytes can also
express perlecan mRNA, supporting our previ-
ous theory. At E16.0, perlecan mRNA expres-
sion was reduced in lower hypertrophic cell
zone, although immunoreactivity was detected
throughout the cartilage matrix. These results
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Figure 3. Condylar anlage/cartilage in coronal plane at E14.0 (a-d), E15.0 (e-h), and
E16.0 (i-l). Toluidine blue staining (a,e,i), and in situ hybridization for perlecan (b,f,j),
DMP1 (c,g,k), and MEPE (d,h,l). Inset in (g) shows a bright field image of identical sec-
tion stained with toluidine blue. a) Although the ossifying mandible was recognizable
(arrowhead), metachromasia was not observed in the condylar anlage (arrow). b-d)
Perlecan, DMP1, and MEPE mRNA expression were not detected in the anlage (arrows
in b-d), but DMP1 mRNA was slightly expressed in cells in the osteoid-like tissue (arrow-
heads in c). e) A metachromatically stained matrix was first detected in the anlage
(arrow); note that newly formed chondrocytes showed a considerable hypertrophy, and
the bone collar had formed around the cartilage (arrowhead). f ) Perlecan mRNA expres-
sion was detected in newly formed chondrocytes (arrows). g) DMP1 mRNA was
expressed in the osteogenic cells of the bone collar (arrowheads) as well as in a few chon-
drocytes (arrows). h) MEPE mRNA expression was barely detected both in the cartilage
(arrow) and the bone collar (arrowhead). i) Cell zones in the condylar cartilage had
become distinct: fibrous cell (articular cell) zone (F), polymorphic cell zone (P), flattened
cell zone (Fl), and hypertrophic cell zone (H). j) Perlecan mRNA was expressed in chon-
drocytes from flattened cell zone to upper hypertrophic cell zone (arrows), but reduced
in the lower hypertrophic cell zone (*). k) DMP1 mRNA was expressed in osteogenic cells
of the bone collar (arrowheads), but not in chondrocytes (arrows). l) MEPE mRNA
expression was not detected in the bone collar (arrowheads) or in the cartilage (arrow).
Scale bars: 100 µm.
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are consistent with results previously
described for aggrecan expression,9 and real-
time PCR in the present study demonstrated
that perlecan mRNA showed a similar expres-
sion pattern to aggrecan mRNA. Thus, these
results indicated that perlecan expression is
concomitant with aggrecan expression during
the process of condylar cartilage formation.
Thus, we believe that perlecan is a component
of an essential cartilage matrix, as perlecan
gene-knockout studies have indicated.15DMP1
DMP1 is primarily expressed in mineralized
tissues such as osteocytes and odonto-
blasts.17,43 DMP1-deficient mice displayed
severe deletion of bone and dentin mineraliza-
tion and an abnormal growth plate, suggesting
that DMP1 play a role in mineralization.
Notably, Feng et al.23 reported that DMP1
mRNA was highly expressed in hypertrophic
chondrocytes within the diaphysis of limb bud
cartilage at E16.0 and in the growth plate of 8-
weeks-old mice. Meanwhile, in limb bud carti-
lage, cartilage marker molecules further divide
the hypertrophic cell zone into upper hyper-
trophic cell zone and lower hypertrophic cell
zone, and the latter expresses OPN as well as
type X collagen.8,44 During initial formation of
the hypertrophic cell zone in limb bud cartilage
(before bone marrow cavity formation), both
OPN and BSP mRNAs are expressed in the
lower hypertrophic cell zone (mineralizing car-
tilage core), although the expression of BSP
mRNA is weaker than that of OPN.8,45 In the
present study, hypertrophic cell zone in the tib-
ial cartilage was first observed at E14.0, and
DMP1 mRNA expression was detected in lower
hypertrophic cell zone; this pattern was similar
to the pattern of OPN mRNA. Thus, DMP1 is
potentially another marker molecule for lower
hypertrophic cell zone in limb bud cartilage. 
In newly formed condylar cartilage at E15.0,
BSP mRNA is more extensively expressed than
OPN mRNA; this pattern differed from that in
limb bud cartilage at the corresponding stage.8
In the present study, DMP1 mRNA was detect-
ed in a few chondrocytes in newly formed
condylar cartilage at E15.0; this pattern was
similar to that of OPN. DMP1 mRNA expres-
sion was, however, hardly detected at E16.0.
Thus DMP1 expression in hypertrophic chon-
drocytes was only transient, and DMP1 may
not have important roles in developing condy-
lar cartilage, compared with OPN and BSP.
Meanwhile, intense DMP1 mRNA expression
was observed both in newly formed bone collar
around the diaphysis of tibial cartilage and
around newly formed condylar cartilage, indi-
cating DMP1 seems to be involved in the for-
mation of bone collar in both types of cartilage.
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Figure 5. Schematic representations of the
expression pattern of perlecan, DMP1, and
MEPE based on the present findings. a)
Condylar anlage/cartilage at E14.0 to
E16.0. b) Tibial cartilage at E13.0 and
E14.0.
Figure 4. The anlage of the future tibia at E12.0 (a-d), and tibial cartilage at E13.0 (e-h),
E14.0 (i-l). Toluidine blue staining (a,e,i) and in situ hybridization for perlecan (b,f,j),
DMP1 (c,g,k), and MEPE (d,h,l). a) The anlage of the future tibia consisted of a mes-
enchymal cell condensation (arrow). b-d) Perlecan, DMP1, and MEPE mRNA were not
expressed in the condensation (arrows). e) A metachromatically stained matrix was first
detected in the anlage of the future tibia (arrow). f ) Perlecan mRNA was expressed in
chondrocytes throughout the cartilage (arrow). g,h) DMP1 and MEPE mRNA were not
detected in tibial cartilage (arrows). i) Proliferative (P), maturation (M), and hyper-
trophic cell zone (H) had become clearly identifiable in the cartilage, and hypertrophic
cell zone could be divided into two zones: the upper hypertrophic cell zone (U) and the
lower hypertrophic cell zone (L). j) Perlecan mRNA was expressed in chondrocytes
throughout the entire proliferative and maturation cell zone (arrows), but expression was
weaker in the hypertrophic cell zone (*). k) DMP1 mRNA was expressed in the
osteogenic cells of the bone collar (arrowheads) and in chondrocytes of the lower hyper-
trophic cell zone (arrows). l) MEPE mRNA expression was not detected both in the bone
collar (arrowhead) or in the cartilage (*). Scale bars: 100 μm.
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In vitro findings suggest that the full-length
DMP1 inhibits mineralization, but N-terminal
and C-terminal fragments promote hydroxyap-
atite formation.46,47 Maciejewska et al.48,49
demonstrated that, in the growth plate of long
bones in newborn rats, N-terminal DMP1 frag-
ments were predominantly localized in the
matrix of the proliferation and hypertrophic
cell zone, while the C-terminal fragments were
primarily localized in the hypertrophic cell
zone and mineralization front, indicating the
C-terminal fragments are involved in cartilage
mineralization. Based on our Western blot
analysis, a protein band of 65 kDa reacted with
anti-DMP1 antibody in bone-derived samples,
confirming that this antibody can recognize C-
terminal fragments of DMP1. Based on
immunohistochemistry, C-terminal fragments
were recognized in the newly formed lower
hypertrophic cell zone in the tibial cartilage at
E14.0; this pattern was identical to that of
DMP1 mRNA expression. These results were
similar to previous finding for the postnatal rat
growth plate,48,49 and we reasoned that C-ter-
minal fragments may also be involved in initial
mineralization of limb bud cartilage. 
Regarding the mandibular condylar carti-
lage, the C-terminal fragments were mainly
localized in the nuclei of chondroblastic and
hypertrophic layers and cartilage-bone inter-
face in postnatal rat condylar cartilage.25 In the
present study, immunoreactivity from C-termi-
nal fragments was barely evident in developing
condylar cartilage; this finding was not consis-
tent with previous findings25 or with our find-
ings for tibial cartilage. These differences
were due to differences in the developmental
stages and species examined, and they sug-
gested that roles of C-terminal fragments in
the developing condylar cartilage may not be
as important as those in the limb bud cartilage.
This is also supported by results of in situ
hybridization described above.MEPE
MEPE is predominantly expressed in osteo-
cytes.26,50,51 In situ hybridization in the present
study confirmed this observation, indicating
that the probes used were reliable markers for
in situ hybridization of this molecule. MEPE-
deficient mice display an increase in bone
mass and enhancement of mineralization;
conversely, MEPE-overexpressing mice had
wider epiphyseal growth plates and expansion
of primary cancellous bone.50,52 Thus, MEPE
may be involved in mineralization of cartilage
matrix, as indicated by a report on MEPE
mRNA expression in hypertrophic chondro-
cytes of the postnatal murine growth plate.30
Nevertheless, the exact role of MEPE in carti-
lage remains unclear. Our previous study31
shows that MEPE immunoreactivity is evident
in Meckel’s cartilage in fetal mice and rats and
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Figure 6. Condylar anlage/cartilage at E14.0 (a-c), E15.0 (d-f ), E16.0 (g-i), and maxillary
region at E16.0 (s,t); t) is the higher magnification of rectangular area of (s). The anlage
of future tibia at E12.0 (j-l), and tibial cartilage at E13.0 (m-o), and E14.0 (p-r).
Immunohistochemistry for perlecan (a,d,g,j,m,p), DMP1 (b,e,h,k,n,q), and MEPE
(c,f,i,l,o,r,s,t). a) Perlecan immunoreactivity was evident in Meckel’s cartilage (M), but
not in the anlage (arrow). b) DMP1 immunoreactivity was weak but definite in the
osteoid-like tissue (arrowhead), but not in the condylar anlage (arrow) or Meckel’s carti-
lage (M). c) MEPE immunoreactivity was not detected in the condylar anlage (arrow),
but it was evident in the osteoid-like tissue (arrowhead) and in Meckel’s cartilage (M). d)
Perlecan immunoreactivity was clearly detected in newly formed cartilage matrix (arrow).
e) DMP1 immunoreactivity was evident in the bone collar (arrowhead), but not in the
cartilage matrix (arrow). f ) MEPE immunoreactivity was evident in the bone collar
(arrowhead) and in the cartilage matrix (arrow). g-i) Immunostaining patterns were sim-
ilar to those of E15.0. j-l) Perlecan, DMP1, and MEPE immunoreactivity were not
detected in the mesenchymal cell condensation (arrows). m-o) Perlecan and MEPE
immunoreactivity was evident in the matrix throughout the cartilage matrix (arrows in
m and o), but DMP1 immunoreactivity was not detected (arrow in n). p) Perlecan
immunoreactitivity was detected throughout the cartilage matrix (arrows). q) DMP1
immunoreactivity was detected in the bone collar (arrowheads) and in the lower hyper-
trophic cell zone (*). r-t) MEPE immunoreactivity was detected in the bone collar (arrow-
heads in r), throughout the cartilage (arrows in r), and in some bone lacunae (arrowheads
in t), but not in the oral epithelium (asterisk in t). Scale bars; a-r) 100 mm; s,t) 80 mm.
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in condylar cartilage in human fetuses, and we
hypothesized that MEPE may be useful as a
marker molecule for cartilage.
To test this hypothesis, we performed in situ
hybridization with a 35S-UTP-labeled RNA
probe for MEPE. No mRNA expression was
detected in any chondrocytes in the tibial car-
tilage or the condylar cartilage, even when
exposure period was extended up to 4 weeks;
this finding was consistent with the results of
our real-time PCR analysis. MEPE immunore-
activity was, however, detected throughout the
cartilage matrix in Meckel’s, tibial, condylar,
and tracheal cartilages, as we previously
described. As negative controls never showed
positive reactions, we believed that this
immunoreactivity was not background stain-
ing. To determine whether this positive reac-
tion was a non-specific reaction, we performed
Western immunoblotting with bone- and tra-
cheal cartilage-derived samples. Previous
Western immunoblotting studies demonstrat-
ed that a protein band of 55 kDa in rat bone53
and 50 kDa in rat dental pulp36 were recog-
nized as full-length MEPE. 
In the present study, a protein band of 62
kDa in bone-derived samples reacted with
antibody, indicating that this antibody could
recognize full-length MEPE. The slight
increase in molecular weight may be due to
differences between species or post-transla-
tional modification, such as phosphorylation
or glycosylation. In cartilage-derived samples,
two bands of 67 kDa and 59 kDa were detected.
Wang et al.36 identified three forms of MEPE
protein, 50, 38, and 25 kDa in rat pulp tissue;
these finding indicate that the low-molecular
weight proteins are cleaved forms of MEPE. We
cannot confirm whether these bands were
products of post-translational modification or
cleaved forms of MEPE, but believe that there
are some proteins that the MEPE antibody can
recognize and that the immunoreactivity in
cartilage was not a non-specific reaction. 
It is conceivable that MEPE protein accumu-
lated gradually in the cartilage, even though
the mRNA expression levels were consistently
below the limits of detection of in situ
hybridization. We cannot, however, confirm
that MEPE is a useful marker molecule for car-
tilage, and we will modify our previous hypoth-
esis. In addition, the exact role of MEPE in
developing condylar/tibial cartilage still
remains unclear, since MEPE immunoreactivi-
ty was evenly recognized throughout cartilage
matrix.
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